

**FACSIMILE COVER SHEET****RECEIVED  
CENTRAL FAX CENTER****APR 29 2005****Licata & Tyrrell P.C.**66 E. Main Street  
Marlton, New JerseyTel: (856) 810-1515  
Fax: (856) 810-1454


April 29, 2005

**TO:** Examiner Haddad (TC1600)**GROUP: 1644****FAX NUMBER:** 703-872-9307**ATTORNEY DOCKET NO.:** PENN-0749**SERIAL NO.:** 09/762,023**FILED:** June 28, 2001**NUMBER OF PAGE:****MESSAGE:** Attached please find Amendment Transmittal Letter; Reply under 37 CFR 1.116 mailed February 10, 2005; and Certificate of Transmission by Facsimile.**Kathleen A. Tyrrell, Registration No. 38,350****URGENT! PLEASE DELIVER IMMEDIATELY  
UPON RECEIPT. THANK YOU!**

If you have any questions, or did not receive the proper number of pages, or had trouble during transmission, please call 856-810-1515.

**CONFIDENTIALITY NOTICE**

The information contained in this facsimile message is legally privileged and confidential, and intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are hereby notified that any unauthorized disclosure, copying distribution or taking of any action in reliance on the contents of the telecopied materials is strictly prohibited and review by any individual other than the intended recipient shall not constitute waiver of the attorney client privilege. If you have received this transmission in error, please immediately notify us by telephone in order to arrange for the return of the materials. Thank you.

<b>CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)</b> Applicant(s): Muzykantov et al.			Docket No. <b>PENN-0749</b>
Application No. <b>09/762,023</b>	Filing Date <b>June 28, 2001</b>	Examiner <b>M. DiBrino</b>	Group Art Unit <b>1644</b>
<b>Invention: TARGETING AND PROLONGING ASSOCIATE OF DRUGS TO THE LUMINAL SURFACE OF THE PULMONARY VASCULAR ENDOTHELIAL CELLS</b>			
<p>I hereby certify that this <u>Reply under 37 CFR 1.116</u> (Identify type of correspondence) is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703-872-9307</u>) on <u>April 29, 2005</u> (Date)</p> <p style="text-align: center;"><b>Kathleen A. Tyrrell</b> (Typed or Printed Name of Person Signing Certificate)  (Signature)</p> <p>Note: Each paper must have its own certificate of mailing.</p>			

<b>AMENDMENT TRANSMITTAL LETTER (Small Entity)</b>				Docket No. PENN-0749	
Applicant(s): Muzykantov et al.					
Application No. 09/762,023	Filing Date June 28, 2001	Examiner M. DiBrino	Customer No. 26259	Group Art Unit 1644	Confirmation No. 7329
Invention: Targeting and Prolonging Association of Drugs to the Luminal Surface of the Pulmonary Vascular Endothelial Cells					
<b>COMMISSIONER FOR PATENTS:</b>					
Transmitted herewith is an amendment in the above-identified application.					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27					
The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	1	20 =	0	x \$25.00	\$0.00
INDEP. CLAIMS	1	3 =	0	x \$100.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1619 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. <b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
 <i>Kathleen A. Tyrrell</i> <i>Signature</i> Kathleen A. Tyrrell, Reg. No. 38,380					
Dated: April 29, 2005					
<div style="border: 1px solid black; padding: 10px;"> I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____.  <p style="text-align: center;">(Date)</p> </div>					
<i>Signature of Person Mailing Correspondence</i>					
<i>Typed or Printed Name of Person Mailing Correspondence</i>					

RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **PENN-0749**  
Inventors: **Muzykantov et al.**  
Serial No.: **09/762,023**  
Filing Date: **June 28, 2001**  
Examiner: **Haddad, Maher M.**  
Customer No.: **26259**  
Group Art Unit: **1644**  
Confirmation No.: **7329**  
Title: **Targeting and Prolonging  
Association of Drugs to the Luminal  
Surface of the Pulmonary Vascular  
Endothelial Cells**

Certificate of Facsimile Transmission

I hereby certify that this document is being facsimile  
transmitted to the Patent and Trademark Office on  
the date shown below.

On April 29, 2005

  
Kathleen A. Tymell, Registration No. 38,350

Mail Stop  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sirs:

Reply under 37 C.F.R. 1.116

This is a reply to the Office Action mailed February  
10, 2005 setting a three (3) month statutory period for

Attorney Docket No.: **PENN-0749**  
Inventors: **Muzykantov et al.**  
Serial No.: **09/762,023**  
Filing Date: **June 28, 2001**  
Page 2

response. Please enter the following remarks into the record.

**Remarks begin on page 3.**

Attorney Docket No.: **PENN-0749**  
Inventors: **Muzykantov et al.**  
Serial No.: **09/762,023**  
Filing Date: **June 28, 2001**  
Page 3

Claim 9: (previously presented) A method for dissolution of fibrin clots in the pulmonary vasculature of an animal comprising conjugating a non-internalizable antibody to ICAM-1 to an anti-thrombotic agent and systemically administering the non-internalizable antibody to ICAM-1 conjugated to an anti-thrombotic agent to an animal so that the non-internalizable antibody to ICAM-1 conjugated to an anti-thrombotic agent binds to the luminal surface of the pulmonary endothelium of the animal and therapeutic action of the anti-thrombotic agent is localized in the blood compartment of the pulmonary vasculature.